If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...

Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma ...

A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Phase I evaluation of the PI3 kinase (PI3K) inhibitor ...

First and Only Personalized Medicine Shown to Help People With BRAF V600E Mutation-Positive Metastatic Melanoma, Found in Half of Melanoma Patients, Live Longer Roche (SIX: RO, ROG; OTCQX: RHHBY) ...

Phase III studies of single agent therapy in metastatic melanoma with BRAF V600 mutations meet primary endpoints Findings from GlaxoSmithKline (GSK) plc's Phase III clinical study programme evaluating ...

First-line immunotherapy for BRAF-positive melanoma, followed by targeted therapy at progression, led to a "clinically meaningful" survival benefit, a randomized trial showed. Combination ...

Validation of the 31-gene expression profile test to stratify melanoma-specific survival in an unselected, prospectively tested cohort of patients with stage IIB-III cutaneous melanoma. This is an ...

Ipsen receives CHMP’s positive opinion on Ojemda for treating monotherapy of children with relapsed or refractory BRAF-altered paediatric low-grade glioma: Paris Wednesday, Marc ...